TTFields enhance downstream antitumor immune response¹

TTFields-mediated cell disruption activates the immune system and triggers an antitumor cell response downstream¹

TTFields lead to the onset of aneuploidy, ER stress, and low intracellular ATP levels, upregulating an autophagic response in cancer cells, as demonstrated in preclinical models.²

TTFields have induced hallmarks of immunogenic cell death, including HMGB1 release, cell surface exposure of calreticulin, and autophagy-mediated ATP release.¹

Watch below to see how TTFields enhance the downstream antitumor immune response

See the enhanced effects of TTFields when used with a PD-1 inhibitor

See how TTFields therapy also impacts DNA damage repair in cancer cells

References: 1. Voloshin T, Kaynan N, Davidi S, et al. Tumor-treating fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy. Cancer Immunol Immunother. 2020;69(7):1191-1204. doi:10.1007/s00262-020-02534-7 2. Shteingauz A, Porat Y, Voloshin T, et al. AMPK-dependent autophagy upregulation serves as a survival mechanism in response to Tumor Treating Fields (TTFields). Cell Death Dis. 2018;9:1074. doi:10.1038/s41419-018-1085-9

TTFields enhance downstream antitumor immune response1

TTFields lead to the onset of aneuploidy, ER stress, and low intracellular ATP levels, upregulating an autophagic response in cancer cells, as demonstrated in preclinical models.2

TTFields have induced hallmarks of immunogenic cell death, including HMGB1 release, cell surface exposure of calreticulin, and autophagy-mediated ATP release.1